Pharma Education Center PEC

pharmaeducationcenter.it

è una Società che ha come missione l'organizzazione di Corsi in house e pubblici di elevato livello culturale nel settore Life Sciences. Nell’organizzazione di PEC, un ruolo chiave per la realizzazione della missione è affidato ai Working Groups; essi costituiscono una comunità scientifica in divenire, che offre agli iscritti opportunità di nuovi contatti, aggiornamento, scambio e condivisione di informazioni e conoscenze tecnico/scientifiche.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CITIUS PHARMACEUTICALS ACHIEVES CHEMICAL MANUFACTURING AND CONTROL MILESTONES FOR MINO-LOK

Citius Pharmaceuticals | September 23, 2020

news image

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has achieved a number of significant milestones over the past several weeks for Mino-Lok®. Mino-Lok is an antibiotic lock solution being developed as an adjunctive therapy for patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloods...

Read More

Pharmacy Market

FOGPHARMA ANNOUNCES $178 MILLION SERIES D FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS HELICON POLYPEPTIDE THERAPEUTICS

FogPharma | November 28, 2022

news image

FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset...

Read More

Pharmacy Market

MEMORIAL HERMANN HEALTH SYSTEM MAKES A STRATEGIC INVESTMENT IN CAPITAL RX CUSTOMER SOLUTIONS PLATFORM

PRNewswire | August 11, 2023

news image

Capital Rx, the health technology company changing the way prescription drugs are priced and patients are cared for in America, has received a strategic investment from Memorial Hermann Health System, a non-profit health system committed to creating healthier Houston communities. Memorial Hermann joins Capital Rx's existing investors in supporting the development of JUDI®, the new standard for backend claims processing platforms in the pharmacy benefit management (PBM) industry, an...

Read More

Pharmacy Market

ATHENEX, INC. REACHES AGREEMENT WITH LENDERS TO PURSUE EXPEDITED SALES PROCESS

Globenewswire | May 16, 2023

news image

Athenex, Inc. a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company’s assets across its primary businesses: Athenex Pharmaceutical Division (“APD”), Orascovery, and Cell Therapy. To be...

Read More
news image

CITIUS PHARMACEUTICALS ACHIEVES CHEMICAL MANUFACTURING AND CONTROL MILESTONES FOR MINO-LOK

Citius Pharmaceuticals | September 23, 2020

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has achieved a number of significant milestones over the past several weeks for Mino-Lok®. Mino-Lok is an antibiotic lock solution being developed as an adjunctive therapy for patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloods...

Read More
news image

Pharmacy Market

FOGPHARMA ANNOUNCES $178 MILLION SERIES D FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS HELICON POLYPEPTIDE THERAPEUTICS

FogPharma | November 28, 2022

FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant Asset...

Read More
news image

Pharmacy Market

MEMORIAL HERMANN HEALTH SYSTEM MAKES A STRATEGIC INVESTMENT IN CAPITAL RX CUSTOMER SOLUTIONS PLATFORM

PRNewswire | August 11, 2023

Capital Rx, the health technology company changing the way prescription drugs are priced and patients are cared for in America, has received a strategic investment from Memorial Hermann Health System, a non-profit health system committed to creating healthier Houston communities. Memorial Hermann joins Capital Rx's existing investors in supporting the development of JUDI®, the new standard for backend claims processing platforms in the pharmacy benefit management (PBM) industry, an...

Read More
news image

Pharmacy Market

ATHENEX, INC. REACHES AGREEMENT WITH LENDERS TO PURSUE EXPEDITED SALES PROCESS

Globenewswire | May 16, 2023

Athenex, Inc. a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the Company’s assets across its primary businesses: Athenex Pharmaceutical Division (“APD”), Orascovery, and Cell Therapy. To be...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us